Return to News
Argos Therapeutics to Present a Corporate Overview, Prospects of its Arcelis™ Immunotherapy and Clinical Developments at 2010 Mid-Atlantic Bio
Durham, NC– October 28, 2010 — Argos Therapeutics today announced that Jeff Abbey, the company´s president and chief executive officer, will present a corporate overview, prospects of its Arcelis™ immunotherapy and clinical developments at the 2010 Mid-Atlantic Bio conference in Bethesda, Md. at 9 a.m. EDT on Friday, Oct. 29, 2010. The conference will take place at the Bethesda North Marriott Hotel & Conference Center.
Argos is in the process of securing funding to begin a Phase 3 trial in renal cell carcinoma (RCC) with its Arcelis immunotherapy, AGS 003, in mid-2011. The company recently presented favorable progression-free survival and safety results from an ongoing Phase 2 trial for AGS 003 in combination with sunitinib.
About the Arcelis™ Technology
Arcelis is Argos´ proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient´s own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patientís disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA (“mRNA”) isolated from the patient´s disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient´s specific disease.
About Argos Therapeutics, Inc.
Argos is an immunotherapy company developing new treatments for cancer, infectious and
autoimmune diseases, and transplantation rejection. The Company has generated multiple
platform technologies and a diverse pipeline of products based on its expertise in the biology of
dendritic cells — the master switch that turns the immune system on or off.
David Schull or Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4271 or (212) 845-4235
[email protected] or [email protected]
print friendly version
# # #